A phase 2 trial of Avalo Therapeutics’ hidradenitis suppurativa (HS) candidate hit its primary endpoint, emboldening the ...
EPCORE FL-2: Phase 3 trial of epcoritamab with rituximab and lenalidomide (R2) vs chemoimmunotherapy or R2 in previously untreated follicular lymphoma. This is an ASCO Meeting Abstract from the 2024 ...
Potent and durable efficacy with iSCIB1+ of 77% progression free survival (PFS) at 20 months, in combination with ipilimumab and nivolumab, ...
The first participant has been dosed in an investigator-led Phase 2 trial testing pegsebrenatide as a potential treatment for ...
Shares of Inhibrx Biosciences rose after the clinical-stage biopharmaceutical company said it would release data from a Phase 2 study of INBRX-106, a potential cancer treatment. Shares were up 6.4% to ...
The MARITIME Phase 3 Chronic Weight Management Studies are Actively Enrolling, and Phase 3 Studies in People Living With Atherosclerotic Cardiovascular Disease, Heart Failure and Obstructive Sleep ...
Buntanetap improved cognition in pTau217-positive early AD patientsThe drug reduced neurotoxic proteins as well as biomarkers of ...
Cohort Achieves 55% Complete Response at Day 57 Emerging as Registrational Grade Lead RegimenPHILADELPHIA, May 06, 2026 ...
– Treatment with the highly selective NaV1.8 pain signal inhibitor suzetrigine met the primary endpoint with a statistically significant and clinically meaningful 2.02 point within-group reduction ...
BioVie Inc. (NASDAQ: BIVI) ('BioVie” or the 'Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that it will host ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results